About the Study

B-Cell Acute Lymphoblastic Leukemia (B-ALL): A clinical trial to study inotuzumab ozogamicin (InO) in combination with chemotherapy in children and young adults with relapsed or refractory B-ALL

The overall goal of this study is to find out what effect, good and/or bad, the medicine inotuzumab ozogamicin (InO) in combination with chemotherapy has on children and young adults with relapsed or refractory B-ALL. The treatment used in this study involves cancer fighting medicine called chemotherapy plus the medicine InO. The treatment on this study takes about 2 months, divided into 2 phases of therapy. Patients must be ≥1 year and < 22 years of age at the time of enrollment.

Interested in learning more?

Full Study Name: AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)